Fluoguide AS FLUO.ST · SEK

Its shares trade on Nasdaq Stockholm under the ticker FLUO.ST. It has been listed since 7 May 2019. In the fiscal year to 31 December 2024, it reported revenue of DKK 572,530 and a net loss of DKK 43.1m. At that date it held total assets of DKK 42.2m and shareholders' equity of DKK 34.3m.

FluoGuide A/S is a clinical stage biotechnology company, which engages in the development of drugs used for the improvement of surgical outcomes by making cancer fluorescent. The firm is a provider of solutions for maximizing surgical outcome through intelligent targeting. FluoGuide develops surgical solutions, which expected to reduce Cancer pain for the patient and increases the possibility of recovering as well as reducing costs for the health care system. The Company’s main product, FG001, is designed using FluoGuide’s uPAR technology platform to improve surgical precision by illuminating cancer cells intraoperatively. FluoGuide explores FG001 in three other severe cancer indications, namely lung, head & neck, meningioma and low grade glioma.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Peter EriksenIndependent Chairman of the Board
• Mr. Morten AlbrechtsenChief Executive Officer
• Mr. Mats ThorenVice Chairman of the Board, since 2021
• Mr. Henrik MoltkeChief Financial Officer
• Mr. Andreas KjaerChief Scientific Officer, Board Member, since 2018
• Ms. Dorthe MejerVice President - Clinical Development
• Mr. Jens EllrichChief Medical Officer
• Dr. Grethe RasmussenChief Development Officer
• Mr. Michael EngsigBoard Member
• Ms. Donna HaireBoard Member

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.